Medicamen Biotech Limited — Important, 03-09-2026: Updates

Medicamen Biotech reported FY26 turnover of ~178.85 Cr & PAT of ~9.41 Cr, with 80% sales from global markets. The company boosted R&D/Capex for sustainability and increased MSME sourcing. A `7,080 fine for a minor filing delay was noted and resolved. Loans to related parties significantly increased.